lancet-header

Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.

Predictive Value of HbA1c for Adverse Prognosis in COVID-19: A Systematic Review and Meta-Analysis

40 Pages Posted: 1 Feb 2021

See all articles by Zheng Zhu

Zheng Zhu

Fujian Medical University - Shengli Clinical Medical College

Yaqian Mao

Fujian Medical University - Shengli Clinical Medical College

Gang Chen

Fujian Medical University - Department of Endocrinology; Fujian Academy of Medical Sciences - Fujian Provincial Key Laboratory of Medical Analysis

More...

Abstract

Background and Aims: Clinical and laboratory predictors of adverse clinical course and death in COVID-19 patients urgently need to be identified. So far, the association between HbA1c and in-hospital mortality of COVID-19 remains a controversial issue. The aim of this study is to analyze predictive value of HbA1c for adverse prognosis in COVID-19.

Methods: We systematically searched both Chinese and English databases using specific keywords associated with our aims until November 21th, 2020. The Newcastle-Ottawa Scale (NOS) was used for quality assessment. A Statistical analysis was carried out using Review Manager 5.3 and STATA 15.1.

Results: Nine clinical trials were included in this study involving 2577 subjects. The results indicate that the association between elevated HbA1c referred as a continuous variable and adverse prognosis of COVID-19 was not significant (OR, 1.02; 95%CI, 0.95-1.09). However, higher HbA1c levels regarded as a dichotomous variable contributed to an increase mortality of COVID-19 (OR, 2.300; 95%CI, 1.679-3.150). Results were stable in a sensitivity analysis. More studies are needed to demonstrate the effect of HbA1c on hospital mortality.

Conclusion: Prolonged uncontrolled hyperglycemia increases the risk of adverse prognosis in COVID-19. Patients with higher HbA1c should be monitored strictly to minimize the risk of adverse prognosis in COVID-19.

Funding Statement: None.

Declaration of Interests: The authors declare no conflict of interests.

Suggested Citation

Zhu, Zheng and Mao, Yaqian and Chen, Gang, Predictive Value of HbA1c for Adverse Prognosis in COVID-19: A Systematic Review and Meta-Analysis. Available at SSRN: https://ssrn.com/abstract=3759711 or http://dx.doi.org/10.2139/ssrn.3759711

Zheng Zhu

Fujian Medical University - Shengli Clinical Medical College

China

Yaqian Mao

Fujian Medical University - Shengli Clinical Medical College

China

Gang Chen (Contact Author)

Fujian Medical University - Department of Endocrinology ( email )

China
+86-1350933707 (Phone)

Fujian Academy of Medical Sciences - Fujian Provincial Key Laboratory of Medical Analysis

China